CA
NEO icon

Calton & Associates’s NeoGenomics NEO Stock Holding History

Calton & Associates’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,278
Closed -$132K – 270
2022
Q4 		$132K Buy
+14,278
New +$133K 0.05% 266
2022
Q2 		– Sell
-10,355
Closed -$125K – 316
2022
Q1 		$125K Buy
+10,355
New +$218K 0.04% 338
2021
Q4 		– Sell
-5,087
Closed -$245K – 398
2021
Q3 		$245K Sell
5,087
-39
-0.8% -$1.8K 0.05% 334
2021
Q2 		$232K Sell
5,126
-159
-3% -$7.04K 0.04% 353
2021
Q1 		$255K Buy
5,285
+480
+10% +$25K 0.05% 311
2020
Q4 		$259K Buy
+4,805
New +$217K 0.05% 295

Other funds holding NEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Calton & Associates's NEO Position: Q1 2023 in Review

Calton & Associates sold out of NeoGenomics (NEO) in Q1 2023, closing a stake of 14,278 shares — an estimated $132K sold.

Calton & Associates first reported a position in NEO in Q4 2020 and held it in 6 quarters. The position peaked at $259K in Q4 2020. 256 funds tracked by Wall St. Rank hold NEO as of Q1 2023.

  • Calton & Associates reported no remaining NeoGenomics position as of Q1 2023 after selling out during the quarter.
  • Calton & Associates sold 14,278 NeoGenomics shares in Q1 2023, an estimated $132K.
  • Calton & Associates first reported a position in NeoGenomics in Q4 2020 and held it in 6 quarters.
  • Calton & Associates's NeoGenomics position peaked at $259K in Q4 2020.
  • 256 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2023.

Based on Calton & Associates's 13F filing for Q1 2023, filed 19 Apr 2023.